Zydus Lifesciences

Zydus Lifesciences receives final USFDA approval for varenicline tablets

The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ

Launches, base biz expansion tonic for Dr Reddy's double-digit growth

While the company's bottom line grew 10.5% annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over next two years, observes ICICI Securities

Zydus Lifesciences Q4 net dips to 24% Rs 397 cr, revenue up 5%

Company says operational performance came amid geopolitical turmoil resulting in supply chain challenges and inflationary pressures

Zydus Lifesciences Q4 profit dips 41% to Rs 397 cr due to higher expenses

The company had posted a consolidated net profit of Rs 679 crore in the same quarter of previous fiscal year, Zydus Lifesciences said in a regulatory filing.

India-developed 'variant-proof' Covid vaccine likely in 2-3 years: Industry

Domestically produced variant-proof jabs are part of a global project to develop vaccines for future epidemics

A first in India: Zydus brings new drug for uncontrolled 'bad' cholesterol

Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of statins

NTAGI meet this week to review vaccine data for 5-12 age group

A senior government official had told Business Standard last week that so far there was no scientific evidence to expand the vaccination programme to young children

DCGI okays emergency use of Zydus' two-jab Covid-19 vaccine for 12 yrs-plus

With this, vaccine will now be administered on day 0 and day 28. Earlier, it was approved as a triple dose on day 0, day 28 and day 56

Covid-19: Zydus gets SEC approval for two-dose regimen of ZyCov-D

Zydus to conduct mixing trials to test vax efficacy after two shots of Covishield/Covaxin

Zydus Lifesciences gets 3 observations from USFDA for Vadodara plant

Zydus Lifesciences on Thursday said the US health regulator has issued three observations after inspecting its Jarod (Vadodara) based manufacturing facility. The US Food and Drug Administration (USFDA) inspected the injectable facility from February 24 to March 10, 2022. The inspection closed with three observations, the drug firm said in a regulatory filing. "We are confident of addressing and resolving the issues to the satisfaction of USFDA. We remain committed to building a quality culture across our entire manufacturing network, and are committed to remain compliant with high standards of good manufacturing practices across our network," Zydus Lifesciences stated. As per the US health regulator, an FDA Form 483 (observation) is issued to a firm's management at the conclusion of an inspection when investigators have observed any conditions that in their judgment may constitute violations of Food Drug and Cosmetic (FD&C) Act and related Act.